These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

581 related articles for article (PubMed ID: 26518722)

  • 21. The influence of phospholipid on the physicochemical properties and anti-tumor efficacy of liposomes encapsulating cisplatin in mice bearing C26 colon carcinoma.
    Alavizadeh SH; Badiee A; Golmohammadzadeh S; Jaafari MR
    Int J Pharm; 2014 Oct; 473(1-2):326-33. PubMed ID: 25051111
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Stealth CD44-targeted hyaluronic acid supramolecular nanoassemblies for doxorubicin delivery: probing the effect of uncovalent pegylation degree on cellular uptake and blood long circulation.
    Han X; Li Z; Sun J; Luo C; Li L; Liu Y; Du Y; Qiu S; Ai X; Wu C; Lian H; He Z
    J Control Release; 2015 Jan; 197():29-40. PubMed ID: 25449802
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lipopepsomes: A novel and robust family of nano-vesicles capable of highly efficient encapsulation and tumor-targeted delivery of doxorubicin hydrochloride in vivo.
    Qiu M; Sun H; Meng F; Cheng R; Zhang J; Deng C; Zhong Z
    J Control Release; 2018 Feb; 272():107-113. PubMed ID: 29355618
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Study of FA12 peptide-modified PEGylated liposomal doxorubicin (PLD) as an effective ligand to target Muc1 in mice bearing C26 colon carcinoma: in silico, in vitro, and in vivo study.
    Biabangard A; Asoodeh A; Jaafari MR; Mashreghi M
    Expert Opin Drug Deliv; 2022 Dec; 19(12):1710-1724. PubMed ID: 36373415
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tumor-specific antibody-mediated targeted delivery of Doxil reduces the manifestation of auricular erythema side effect in mice.
    Elbayoumi TA; Torchilin VP
    Int J Pharm; 2008 Jun; 357(1-2):272-9. PubMed ID: 18329201
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Surrogate MRI markers for hyperthermia-induced release of doxorubicin from thermosensitive liposomes in tumors.
    Peller M; Willerding L; Limmer S; Hossann M; Dietrich O; Ingrisch M; Sroka R; Lindner LH
    J Control Release; 2016 Sep; 237():138-46. PubMed ID: 27364227
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Liposomal formulation of Galbanic acid improved therapeutic efficacy of pegylated liposomal Doxorubicin in mouse colon carcinoma.
    Nik ME; Malaekeh-Nikouei B; Amin M; Hatamipour M; Teymouri M; Sadeghnia HR; Iranshahi M; Jaafari MR
    Sci Rep; 2019 Jul; 9(1):9527. PubMed ID: 31267009
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Doxorubicin in TAT peptide-modified multifunctional immunoliposomes demonstrates increased activity against both drug-sensitive and drug-resistant ovarian cancer models.
    Apte A; Koren E; Koshkaryev A; Torchilin VP
    Cancer Biol Ther; 2014 Jan; 15(1):69-80. PubMed ID: 24145298
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparative plasma and tissue distribution of Sun Pharma's generic doxorubicin HCl liposome injection versus Caelyx
    Burade V; Bhowmick S; Maiti K; Zalawadia R; Jain D; Rajamannar T
    Cancer Chemother Pharmacol; 2017 May; 79(5):899-913. PubMed ID: 28349166
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tumor targeting of doxorubicin by anti-MT1-MMP antibody-modified PEG liposomes.
    Hatakeyama H; Akita H; Ishida E; Hashimoto K; Kobayashi H; Aoki T; Yasuda J; Obata K; Kikuchi H; Ishida T; Kiwada H; Harashima H
    Int J Pharm; 2007 Sep; 342(1-2):194-200. PubMed ID: 17583453
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hyaluronic acid modified pH-sensitive liposomes for targeted intracellular delivery of doxorubicin.
    Paliwal SR; Paliwal R; Agrawal GP; Vyas SP
    J Liposome Res; 2016 Dec; 26(4):276-87. PubMed ID: 26784587
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Folate receptor-targeted multimodal polymersomes for delivery of quantum dots and doxorubicin to breast adenocarcinoma: In vitro and in vivo evaluation.
    Alibolandi M; Abnous K; Sadeghi F; Hosseinkhani H; Ramezani M; Hadizadeh F
    Int J Pharm; 2016 Mar; 500(1-2):162-78. PubMed ID: 26802496
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A novel cancer targeting approach based on estrone anchored stealth liposome for site-specific breast cancer therapy.
    Paliwal SR; Paliwal R; Mishra N; Mehta A; Vyas SP
    Curr Cancer Drug Targets; 2010 May; 10(3):343-53. PubMed ID: 20370682
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cetuximab-oxaliplatin-liposomes for epidermal growth factor receptor targeted chemotherapy of colorectal cancer.
    Zalba S; Contreras AM; Haeri A; Ten Hagen TL; Navarro I; Koning G; Garrido MJ
    J Control Release; 2015 Jul; 210():26-38. PubMed ID: 25998052
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Doxorubicin-loaded nanocarriers: A comparative study of liposome and nanostructured lipid carrier as alternatives for cancer therapy.
    Fernandes RS; Silva JO; Monteiro LOF; Leite EA; Cassali GD; Rubello D; Cardoso VN; Ferreira LAM; Oliveira MC; de Barros ALB
    Biomed Pharmacother; 2016 Dec; 84():252-257. PubMed ID: 27664949
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Reversibly crosslinked hyaluronic acid nanoparticles for active targeting and intelligent delivery of doxorubicin to drug resistant CD44+ human breast tumor xenografts.
    Zhong Y; Zhang J; Cheng R; Deng C; Meng F; Xie F; Zhong Z
    J Control Release; 2015 May; 205():144-54. PubMed ID: 25596560
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Liposomal doxorubicin for active targeting: surface modification of the nanocarrier evaluated in vitro and in vivo: challenges and prospects.
    Jakoby J; Beuschlein F; Mentz S; Hantel C; Süss R
    Oncotarget; 2015 Dec; 6(41):43698-711. PubMed ID: 26497207
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tumor targeting using anti-her2 immunoliposomes.
    Park JW; Kirpotin DB; Hong K; Shalaby R; Shao Y; Nielsen UB; Marks JD; Papahadjopoulos D; Benz CC
    J Control Release; 2001 Jul; 74(1-3):95-113. PubMed ID: 11489487
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Vascular targeting of doxorubicin using cationic liposomes.
    Wu J; Lee A; Lu Y; Lee RJ
    Int J Pharm; 2007 Jun; 337(1-2):329-35. PubMed ID: 17275230
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Estrogen-functionalized liposomes grafted with glutathione-responsive sheddable chotooligosaccharides for the therapy of osteosarcoma.
    Yin X; Feng S; Chi Y; Liu J; Sun K; Guo C; Wu Z
    Drug Deliv; 2018 Nov; 25(1):900-908. PubMed ID: 29644882
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 30.